What is this medicine?
SUGAMMADEX (soo GAM ma dex) is used to reverse the effects of the muscle relaxants rocuronium and vecuronium. These drugs are given to patients during surgery.
How should I use this medicine?
This medicine is for injection into a vein. It is given by a health care professional in a hospital or clinic setting.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
allergic reaction like skin rash, itching or hives, swelling of the face, lips, or tongue
signs and symptoms of a dangerous change in heartbeat or heart rhythm like chest pain; dizziness; fast or irregular heartbeat; palpitations; feeling faint or lightheaded, falls; breathing problems
signs and symptoms of low blood pressure or a slow heartbeat like dizziness; feeling faint or lightheaded, falls; unusually weak or tired
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
pain at the injection site
What may interact with this medicine?
This medicine may interact with the following medicines:
birth control pills, patches, rings, or injections
What if I miss a dose?
This does not apply.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
an unusual or allergic reaction to sugammadex, other medicines, foods, dyes, or preservatives
pregnant or trying to get pregnant
What should I watch for while using this medicine?
Your condition will be monitored carefully while you are receiving this medicine.
Birth control pills, patches, rings, or injections may not work properly while you are taking this medicine. Females should use an additional, non-hormonal method of birth control (such as condoms or spermicidal jelly) for 7 days after receiving this medicine.
September 30, 2017